Fig. 4
From: Recent advances in systemic therapy for hepatocellular carcinoma
Signaling pathways and molecular targeted therapies for HCC. * represents monotherapies approved by the FDA, ** represents agents as a component of combination therapy approved by the FDA. This figure was modified from Mossenta, et al. [10]. Note: This is an open access article distributed under the Creative Commons Attribution License that permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0)